Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance

Correction: Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)

(2014) Tong Shen et al.   PLoS One

Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance

(2012) Csilla Hegedüs et al.   BIOCHEMICAL PHARMACOLOGY

Macromolecular Changes in Nilotinib Resistant K562 Cells; an In vitro Study by Fourier Transform Infrared Spectroscopy

(2012) Cagatay Ceylan et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation

(2011) Yusuf Baran et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

(2009) Timothy Hughes et al.   JOURNAL OF CLINICAL ONCOLOGY

Sphingosine 1-phosphate induces Mcl-1 upregulation and protects multiple myeloma cells against apoptosis

(2008) Qing-Fang Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Bcl-2-family proteins and hematologic malignancies: history and future prospects

(2008) J. C. Reed   BLOOD

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

(2008) F.-X. Mahon et al.   CANCER RESEARCH

Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells

(2008) E Bonhoure et al.   LEUKEMIA